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CLOZAPINE DEATHS
Antibody deficiency in patients taking clozapine
Mark J Ponsford ST5 clinical immunology and Welsh clinical academic trainee, Stephen Jolles
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Immunodeficiency Centre for Wales, Cardiff CF14 4XW, UK
Although clozapine reduces overall mortality in schizophrenia,1
a growing body of evidence links its use with higher rates of
admission to hospital for pneumonia2-4 and mortality.5-8 Various
mechanisms have been proposed for the rise in pneumonia,
including sedation, sialorrhoea and aspiration, agranulocytosis,
and smoking.9 10 Following the introduction of calculated
globulin screening in Wales,11 we found a novel and striking
association between use of the antipsychotic clozapine and
antibody deficiency.12 Patients taking clozapine follow an
intensive regimen of blood testing for the rare risk of
agranulocytosis (with cumulative incidence of <1% cases), but
antibody testing is not included in existing clozapine monitoring
programmes. We urge consideration of this potential mechanistic
explanation as a modifiable risk factor for the higher rates of
pneumonia and sepsis related mortality reported in this
vulnerable cohort.
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